Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: iTBS Study for Depression (Randomized) [NA]
A completed randomized trial evaluating iTBS for depression and executive dysfunction with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome [Phase 2]
Phase 2 clinical trial investigating plasma exosomal microRNAs as biomarkers for suicidality and treatment outcome in major depressive disor…
-
FDA approval · 2022-06-29FDA Approved: VENLAFAXINE — Original Application (Almatica Pharma LLC)
The FDA approved an Original Application for Venlafaxine from Almatica Pharma LLC. Venlafaxine is indicated for major depressive disorder, g…
-
FDA approval · 2022-06-28FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application from Granules Pharmaceuticals Inc. to approve a bupropion hydrochloride granule formulation unde…
-
FDA approval · 2022-06-27FDA Approved: TRANYLCYPROMINE — Original Application (Solco Healthcare US, LLC)
FDA approves an original application for generic tranylcypromine, a monoamine oxidase inhibitor used for major depressive disorder, manufact…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-24FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved an original application for doxepin hydrochloride as a generic product manufactured by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2022-06-23FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Slate Run Pharmaceuticals, LLC)
The FDA approved a supplemental application for a generic Bupropion hydrochloride sustained-release product from Slate Run Pharmaceuticals, …
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: Antidepressant Trial With P2X7 Antagonist JNJ-54175446 [Phase 2]
Phase 2 trial update for JNJ-54175446 (P2X7 antagonist) in major depressive disorder with inflammation; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode [Phase 3]
Phase 3 clinical trial evaluating LABCAT TCJUSS for depressive episode was terminated.
-
FDA approval · 2022-06-16FDA Approved: QUETIAPINE FUMARATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic quetiapine fumarate under an Original Application. The product will be used for the same indica…
-
FDA approval · 2022-06-14FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for bupropion hydrochloride from Rising Pharma Holdings, Inc., authorizing the generic product's…
-
FDA approval · 2022-06-08FDA Approved: ESCITALOPRAM — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
The FDA approved a supplemental application for a generic escitalopram oxalate product from Jubilant Cadista Pharmaceuticals Inc., authorizi…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Outcomes Mandate National Integration With Cannabis as Medicine [Phase 2]
Phase 2 clinical trial update focusing on integrating cannabis as medicine for various chronic pain conditions, with status currently UNKNOW…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Treatments for Improving Mood in Depressed Teens-3 [NA]
A completed clinical trial investigating treatments for improving mood in depressed teens; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Advancing Personalized Antidepressant Treatment Using PET/MRI [Phase 4]
Phase 4 clinical trial updating personalized antidepressant treatment using PET/MRI in depression has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females [Phase 4]
Phase 4 randomized trial evaluating placebo-controlled augmentation with 5-hydroxytryptophan and creatine in women with treatment-resistant …
-
FDA approval · 2022-05-27FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for aripiprazole filed by Amneal Pharmaceuticals LLC (generic aripiprazole).
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression [Phase 3]
Phase 3 study evaluating the efficacy, pharmacokinetics, safety and tolerability of flexible doses of intranasal esketamine plus an oral ant…
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Optimizing Outcomes of Treatment-Resistant Depression in Older Adults [Phase 4]
Phase 4 trial update evaluating outcomes for treatment-resistant depression in older adults; results were posted in May 2022.
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa [Phase 4]
Phase 4 trial investigating whether Levodopa reverses inflammation-related neurocircuitry alterations associated with depression; study comp…
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Scaling Up Science-based Mental Health Interventions in Latin America [NA]
Completed clinical trial evaluating science-based mental health interventions in Latin America addressing depression and problematic alcohol…
-
CLINICAL_TRIALS trial_result · 2022-05-12Clinical Trial Update: Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder. [Phase 2]
Phase 2 trial comparing memory effects of gamma-hydroxybutyrate versus trazodone in major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2022-05-12Clinical Trial Update: Tracking Depression Symptoms With a Health Chatbot [NA]
Completed clinical trial evaluating a health chatbot for tracking depression symptoms.
-
CLINICAL_TRIALS research · 2022-05-10Clinical Trial Update: Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause" [Phase 4]
A Phase 4 trial investigating the effects of a Tissue Selective Estrogen Complex (TSEC) on depression and reward system activity in perimeno…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care [Phase 2]
Phase 2 trial evaluating ketamine for depression in cancer patients receiving palliative care has been completed.